The Nonpalpable Mammographic Breast Cancer: Diagnosis and Treatment

Educational disclaimer. This article is provided for medical education. It is not a substitute for individualized clinical judgment, current institutional protocols, or formal society guidelines. Decisions about breast cancer screening, biopsy, surgery, radiation, axillary management, and adjuvant therapy should be made by appropriately trained multidisciplinary teams using the most up-to-date guidance from NCCN, ACR, ASTRO, ASBrS, ASCO, ESMO, USPSTF, and local cancer center protocols.

Introduction

Mammographic screening identifies breast cancers that are smaller, more often noninvasive, and less often node-positive than cancers that present as palpable masses. The case presented illustrates this clinical scenario—a 45-year-old woman with a nonpalpable cluster of microcalcifications ultimately shown to harbor multifocal DCIS. The diagnostic and therapeutic frameworks are defined by:

Historical case report (1980’s)

This forty-five-year-old lady, LJ, presented with a two-year history of pain in her right breast. Menarche was at age 15 years. She was nulliparous and had no personal or family history of breast cancer. Six years prior to presentation she had total abdominal hysterectomy and bilateral salpingo-oophorectomy for uterine leiomyomata and hydrosalpinx. On physical examination she was found to have mild tenderness over the upper quadrants of the right breast. There were no palpable breast masses and the rest of her examination was normal. Her serum urea, electrolytes and creatinine were normal. Her serum total proteins measured 63 g/L, albumin 37 g/L, globulin 26 g/L, total bilirubin 9 μmol/L, alkaline phosphatase 37 IU/L, GGT 15 IU/L, SGOT 30 IU/L, calcium 2.45 mmol/L, phosphorus 1.2 mmol/L. Chest radiograph was normal. Bilateral mammography showed a cluster of microcalcifications in the inner upper quadrant of the right breast (Fig 1).

The microcalcifications in the breast were localised by a straight wire placed under mammographic guidance. Mammographic wire localization (MWL) biopsy was then performed under local anaesthesia but specimen radiography was not available. Histopathological examination did not show any calcifications or other abnormality, and repeat mammography showed the microcalcifications to persist. Repeat MWL biopsy under local anaesthesia returned a histology of multifocal in situ ductal carcinoma with extensive cancerization of the lobules. The patterns of intraductal carcinoma discerned included comedo, solid and clinging subtypes containing scattered foci of microcalcification. The surrounding breast tissue demonstrated features of fibrocystic disease. The patient had a mastectomy without axillary dissection for multifocal ductal carcinoma in situ. Histopathological examination of the mastectomy specimen showed no residual tumor and four out of four lymph nodes identified had no metastases. The patient’s postoperative course was uneventful. One year and six months after surgery, surveillance contralateral mammography was normal and at two-years follow-up she had no evidence of tumor recurrence or metastases.

Modern equivalent: A patient presenting today with the same imaging finding would be managed differently in several respects:

  • Reporting and risk categorization. A cluster of suspicious microcalcifications would be characterized by BI-RADS lexicon (e.g., grouped fine pleomorphic calcifications), reported with a final BI-RADS category (typically 4B–5 for findings like LJ’s), and triaged for image-guided biopsy (ACR BI-RADS v2025).
  • Diagnosis. First-line tissue diagnosis would be stereotactic vacuum-assisted core needle biopsy, not open wire-localization biopsy. Open surgical excisional biopsy is reserved for technically inaccessible lesions, discordant radiology–pathology, or selected upgrade-risk lesions.
  • Localization for definitive surgery. Following biopsy-proven multifocal DCIS, lesions would be localized for definitive excision using either a traditional hookwire or a wire-free device such as a radar reflector (SCOUT), magnetic seed (Pintuition), radioactive seed, or radiofrequency tag, each of which decouples imaging-guided placement from surgery and reduces same-day scheduling constraints (Wright et al., SCOUT vs Pintuition, 2025).
  • Surgical management. Multifocal DCIS in a single quadrant may still be amenable to breast-conserving surgery (BCS) with whole-breast radiation if clear margins (≥2 mm) can be achieved with acceptable cosmesis. Truly multicentric DCIS, extensive disease across quadrants, contraindications to radiation, or patient preference would lead to total (simple) mastectomy, generally with SLNB at the same operation because subsequent SLNB is technically impossible after mastectomy (NCCN Breast Cancer v5.2025).
  • No routine SLNB for DCIS treated by BCS. For pure DCIS treated by lumpectomy without mastectomy, SLNB is generally not indicated; it is considered selectively when the upgrade risk to invasive disease is high.
  • Adjuvant endocrine therapy. For ER-positive DCIS treated with BCS, adjuvant tamoxifen (premenopausal or postmenopausal) or aromatase inhibitor (postmenopausal) is offered for ipsilateral and contralateral risk reduction per NSABP B-24 and NSABP B-35. In this patient (already postoophorectomy), an aromatase inhibitor would be the preferred option if ER positive.
  • Surveillance. Modern follow-up is governed by NCCN: history and physical every 4–6 months for 5 years then annually; the first surveillance mammogram of the conserved breast 6–12 months after completion of radiation, then annually; breast MRI for high-risk subgroups; bone-health monitoring for women on aromatase inhibitors.

Discussion

1. Mammography and nonpalpable cancers

Screen-detected cancers are smaller, more often noninvasive, and less often node-positive than cancers that present clinically. Historical terminology such as “minimal breast cancer” (≤5 mm invasive or any in situ; Gallager and Martin, 1971) has been replaced by the AJCC TNM 8th edition lexicon: T1mi (microinvasive, ≤1 mm), T1a (≤5 mm), T1b (≤10 mm), and T1c (≤20 mm). Screening is now organized around the USPSTF 2024 recommendation (biennial mammography 40–74) and parallel ACR and ACS statements that recommend annual screening starting at age 40 for average-risk women. Risk-stratified supplemental imaging (MRI or contrast-enhanced mammography) is recommended for women at high lifetime risk (e.g., germline pathogenic variants, prior chest irradiation, or a calculated lifetime risk ≥20%), with emerging evidence supporting supplemental MRI for women with extremely dense breasts (BCSC modeling, 2026). The FDA’s 2023/2024 final rule requires that all mammography reports include patient-directed information about breast density.

2. Mammographic appearances of cancer

Modern reporting uses the BI-RADS lexicon (ACR BI-RADS v2025):

  • Calcifications: typically-benign morphologies (skin, vascular, coarse popcorn-like, large rod-like, round, rim, dystrophic, milk-of-calcium, suture, eggshell) and suspicious morphologies (amorphous, coarse heterogeneous, fine pleomorphic, fine linear, fine linear branching). Distribution is described as diffuse, regional, grouped, linear, or segmental. Fine linear and fine linear branching calcifications remain strongly suggestive of DCIS, especially comedo-type.
  • Masses are described by shape (oval, round, irregular), margin (circumscribed, obscured, microlobulated, indistinct, spiculated), and density (high, equal, low, fat-containing). Spiculated, irregular, or indistinct margins carry the highest PPV for malignancy.
  • Architectural distortion, asymmetry (focal, global, developing), and calcifications associated with a mass are separate categories.

Each finding receives a final BI-RADS category from 0 (incomplete) through 6 (biopsy-proven malignancy). Categories 4 and 5 trigger image-guided biopsy.

3. Localization and biopsy: image-guided percutaneous core needle biopsy

Modern diagnosis of nonpalpable BI-RADS 4 or 5 lesions is by image-guided percutaneous core needle biopsy:

  • Stereotactic vacuum-assisted biopsy for calcifications and asymmetric densities.
  • Ultrasound-guided core needle biopsy for masses visible on ultrasound and for axillary node assessment.
  • MRI-guided biopsy for MRI-only lesions.

Open surgical biopsy for diagnosis is reserved for lesions that cannot be sampled percutaneously, for radiology–pathology discordance, and for selected high-risk lesions (e.g., atypical ductal hyperplasia, papillary lesions, radial scars) where excisional biopsy is needed to exclude an upgrade.

Wire and wire-free localization are used for excision of biopsy-proven malignancy (or of high-risk lesions requiring excision). Options include traditional hookwire, radioactive seed (e.g., I-125), radar reflector (SCOUT), magnetic seed (Pintuition), and radiofrequency tag (LOCalizer); contemporary comparative data show high success and accuracy for both SCOUT and Pintuition, with shorter operative times reported for some magnetic-seed systems (Wright et al., 2025).

Margin standards are now based on consensus guidelines:

  • Invasive breast cancer treated with whole-breast irradiation: no ink on tumor (SSO-ASTRO 2014).
  • DCIS treated with whole-breast irradiation: ≥2 mm margin (SSO-ASTRO-ASCO 2016).
  • For partial-breast irradiation or omission of radiation, wider margins may be preferred.

4. Specimen radiography

Postexcision specimen radiography (with or without intraoperative specimen tomosynthesis) remains standard for confirming excision of mammographic calcifications or biopsy markers and for orienting the specimen for pathology to guide further margin assessment.

5. Breast ultrasound, tomosynthesis, MRI, and contrast-enhanced mammography

Modern breast imaging extends well beyond 2D mammography:

  • Digital breast tomosynthesis (DBT) is now a primary screening modality in many settings, with improved cancer detection and lower recall rates compared with 2D mammography alone.
  • Breast ultrasound is the workhorse adjunct: targeted evaluation of mammographic masses, axillary node assessment, image-guided biopsy, and supplemental screening in dense breasts.
  • Breast MRI is used for high-risk screening (lifetime risk ≥20%, BRCA1/2 and other high-penetrance pathogenic variants, prior chest radiation), preoperative staging in selected cancers (e.g., invasive lobular carcinoma, occult primary, contralateral evaluation in young women), problem-solving, and response assessment in neoadjuvant therapy.
  • Contrast-enhanced mammography (CEM) uses dual-energy mammography after iodinated contrast to produce a low-energy mammogram plus a recombined image and is increasingly used as an alternative to MRI for problem-solving, supplemental screening in dense breasts, and preoperative extent assessment (Sorin et al., CEM review, 2024).

6. Pathology and biomarkers

Modern breast pathology reports include: histologic type, Nottingham grade, tumor size, lymphovascular invasion, margin status, ER, PR, and HER2 (IHC with ISH per ASCO/CAP), and Ki-67. For ER+/HER2− node-negative invasive breast cancer, validated multigene assays (Oncotype DX Recurrence Score per TAILORx; MammaPrint per MINDACT; EndoPredict; Prosigna/PAM50) guide decisions about adjuvant chemotherapy. Microinvasion is now defined as invasive focus ≤1 mm (T1mi) by AJCC TNM 8th edition. DCIS is graded by nuclear grade with comedo necrosis as a separate histologic feature; pleomorphic LCIS is recognized as a higher-risk variant managed like DCIS.

7. Axillary management: from ALND to sentinel lymph node biopsy

  • Sentinel lymph node biopsy (SLNB) is the staging operation for clinically node-negative invasive breast cancer (NSABP B-32 and subsequent trials).
  • ALND can be omitted in patients meeting ACOSOG Z0011 criteria: cT1–T2 invasive cancer, clinically node-negative axilla, 1–2 positive sentinel nodes, BCS + whole-breast radiation, and no neoadjuvant therapy.
  • Routine SLNB is not indicated for pure DCIS treated by BCS; SLNB is performed when mastectomy is planned for DCIS (because the lymphatic anatomy is disrupted) or when there is a high pre-operative suspicion that occult invasion will be found.
  • After neoadjuvant systemic therapy, axillary staging follows trial-validated algorithms (SENTINA, ACOSOG Z1071, SN-FNAC) integrated into the NCCN guidelines.

8. DCIS management

DCIS represents approximately 20–25% of screen-detected breast cancers. Modern management is shaped by extent, margins, grade, ER/PR status, age, and patient preference:

  • Breast-conserving surgery (lumpectomy) with margins ≥2 mm plus whole-breast radiation is standard for most DCIS, supported by the long-term reductions in ipsilateral breast tumor recurrence (IBR) in NSABP B-17, EORTC 10853, and SweDCIS.
  • Good-risk DCIS: RTOG 9804 long-term results confirm a substantial reduction in 15-year IBR with radiation after lumpectomy for good-risk DCIS (low/intermediate grade, ≤2.5 cm, margins ≥3 mm), with absolute IBR approximately 1.5% with RT vs 9.2% without. Selected patients with very low-risk disease may decline radiation after shared decision-making.
  • Non-low-risk DCIS: the BIG 3-07/TROG 07.01 trial demonstrates a significant reduction in local recurrence with a tumor-bed boost (16 Gy in 8 fractions) after whole-breast radiation.
  • Endocrine therapy for ER-positive DCIS reduces ipsilateral and contralateral breast cancer events: tamoxifen 20 mg daily for 5 years per NSABP B-24, or anastrozole for postmenopausal women per NSABP B-35, which showed superiority for anastrozole on the primary endpoint of breast cancer–free interval.
  • Mastectomy is reserved for diffuse or multicentric DCIS, contraindications to radiation, large lesion-to-breast ratio precluding cosmetic BCS, recurrence after BCS + RT, and patient preference. When mastectomy is performed for DCIS, SLNB is performed concurrently.
  • Active monitoring for low-risk DCIS is emerging as an option. The COMET trial (JAMA 2025) randomized 995 women aged ≥40 with newly diagnosed hormone receptor-positive grade 1 or 2 DCIS to active monitoring vs guideline-concordant care (surgery ± radiation); at 2 years, the cumulative rate of ipsilateral invasive cancer was 4.2% vs 5.9% (noninferior). Longer-term follow-up is ongoing; eligible patients should be informed of this evidence and the trade-offs between immediate surgery and active monitoring.

9. Treatment of early-stage invasive breast cancer

For clinical T1–T2, N0 invasive breast cancer, breast-conserving surgery with whole-breast radiation is the standard locoregional treatment when margins (no ink on tumor) and cosmesis are achievable. Hypofractionated whole-breast radiation (e.g., 40 Gy in 15 fractions; ultrahypofractionated 26 Gy in 5 fractions per FAST-Forward) is now standard for most patients. Partial-breast irradiation is an option for selected low-risk patients per ASTRO/ESTRO guidance. Modern systemic therapy follows the NCCN Breast Cancer v5.2025 framework and is selected by tumor biology (ER, PR, HER2, Ki-67, multigene assays), nodal status, and patient factors; neoadjuvant therapy is increasingly used for triple-negative and HER2-positive disease and for selected hormone-receptor–positive disease. Genetic testing (BRCA1, BRCA2, PALB2, ATM, CHEK2, TP53, PTEN, CDH1) influences surgical choice (bilateral mastectomy for pathogenic variants), screening intensity, and selection of systemic therapy (e.g., PARP inhibitor olaparib for selected BRCA carriers).

10. ADH, classic LCIS, and pleomorphic LCIS

  • Atypical ductal hyperplasia (ADH) on core needle biopsy: surgical excision is recommended because of a 10–30% upgrade rate to DCIS or invasive cancer. Risk-reducing endocrine therapy (tamoxifen, raloxifene, aromatase inhibitor) is offered per NCCN Breast Cancer Risk Reduction Guidelines (Krishnamurthy et al., ADH/LIN review, 2024).
  • Classic lobular carcinoma in situ (LCIS): a risk indicator for bilateral breast cancer (~1% per year). Management is intensified surveillance ± endocrine chemoprevention. Routine excision is not required when imaging-pathology concordant; excision is performed for discordance or for incidental LCIS at the margin of a malignancy.
  • Pleomorphic LCIS: treated like DCIS with surgical excision to clear margins.

11. Recurrence and survival

Modern outcomes in screen-detected breast cancer are markedly improved over the 1980s baseline:

  • DCIS treated with BCS + WBRT has a 10-year IBR of approximately 8–13% overall, lower in good-risk disease and lower again with a tumor-bed boost in non-low-risk disease (RTOG 9804 long-term; BIG 3-07/TROG 07.01).
  • DCIS-specific mortality is approximately 1–3% at 10 years and ≤5% at 20 years across modern series.
  • Stage I invasive breast cancer has 5-year breast cancer–specific survival exceeding 95% with modern multimodal therapy.
  • Salvage of ipsilateral breast tumor recurrence after BCS + WBRT, especially with mastectomy, remains effective and is associated with a more favorable prognosis than chest-wall recurrence after mastectomy.

Conclusion

Mammographic detection of nonpalpable breast cancer remains a cornerstone of breast cancer mortality reduction, and most screen-detected cancers are amenable to breast-conserving therapy with excellent locoregional control. The modern care pathway differs from the 1980s framework in nearly every step: BI-RADS-driven imaging, image-guided percutaneous core needle biopsy as the diagnostic standard, wire or wire-free localization for excision of biopsy-proven malignancy, modern margin standards, sentinel lymph node biopsy under the Z0011 paradigm, breast-conserving therapy with hypofractionated radiation for most early-stage invasive disease, NCCN-aligned DCIS management including endocrine therapy and emerging active monitoring for low-risk lesions, risk-stratified screening and supplemental imaging, and multidisciplinary care. The historical case presented here helps illuminate how dramatically the care of nonpalpable breast cancer has been redefined since the 1980s.

References

American College of Radiology. ACR BI-RADS Atlas: Breast Imaging Reporting and Data System, 5th Edition (v2025 Update). Reston, VA: American College of Radiology, 2025. Link: https://www.acr.org/Clinical-Resources/Publications-and-Research/ACR-Bulletin/2026/definitive-guide-to-breast-imaging.

Bigenwald, R. Z., et al. “NCCN Guidelines Insights: Breast Cancer, Version 5.2025.” Journal of the National Comprehensive Cancer Network (2025). Link: https://pubmed.ncbi.nlm.nih.gov/41213254/.

Bijker, N., P. Meijnen, J. L. Peterse, et al. “Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma-in-Situ: Ten-Year Results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853.” Journal of Clinical Oncology 24, no. 21 (2006): 3381–3387. Link: https://pubmed.ncbi.nlm.nih.gov/16648510/.

Breast Cancer Surveillance Consortium. “Supplemental Breast MRI for Women with Extremely Dense Breasts: Modeling Study.” 2026. Link: https://www.bcsc-research.org/index.php/bcsc-blog/Supplemental-Breast-MRI-to-Women-with-Extremely-Dense-Breasts.

Chua, B. H., A. Link, T. Kunkler, et al. “Radiation Doses and Fractionation Schedules in Non-Low-Risk Ductal Carcinoma in Situ in the Breast (BIG 3-07/TROG 07.01): A Randomised, Factorial, Multicentre, Open-Label, Phase 3 Study.” Lancet Oncology 23, no. 9 (2022): 1093–1106. Link: https://pubmed.ncbi.nlm.nih.gov/35934006/.

Fisher, B., S. Land, E. Mamounas, et al. “Prevention of Invasive Breast Cancer in Women with Ductal Carcinoma in Situ: An Update of the National Surgical Adjuvant Breast and Bowel Project Experience (NSABP B-17 and B-24).” Seminars in Oncology 28, no. 4 (2001): 400–418. Link: https://pubmed.ncbi.nlm.nih.gov/10623018/.

Giuliano, A. E., et al. “Axillary Dissection vs No Axillary Dissection in Women with Invasive Breast Cancer and Sentinel Node Metastasis (ACOSOG Z0011): Long-Term Follow-Up.” Z0011 review (2025). Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC12001651/.

Hwang, E. S., L. J. Pierce, S. M. Rosenberg, et al. “Active Monitoring with or without Endocrine Therapy for Low-Risk Ductal Carcinoma in Situ: The COMET Randomized Clinical Trial.” JAMA 333, no. 11 (2025): 972–980. Link: https://pubmed.ncbi.nlm.nih.gov/39665585/.

Krishnamurthy, S., et al. “Atypical Ductal Hyperplasia and Lobular In Situ Neoplasm: Upgrade Rates and Disease-Free Survival.” 2024. Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10886664/.

Margolese, R. G., S. Cecchini, T. B. Julian, et al. “Anastrozole versus Tamoxifen in Postmenopausal Women with Ductal Carcinoma in Situ Undergoing Lumpectomy plus Radiotherapy (NSABP B-35): A Randomised, Double-Blind, Phase 3 Clinical Trial.” Lancet 387, no. 10021 (2016): 849–856. Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC4792688/.

McCormick, B., K. Winter, C. Hudis, et al. “Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma in Situ: Long-Term Report from NRG Oncology/RTOG 9804.” Journal of Clinical Oncology 39, no. 32 (2021): 3574–3582. Link: https://pubmed.ncbi.nlm.nih.gov/34406870/.

Moran, M. S., S. J. Schnitt, A. E. Giuliano, et al. “Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer.” Journal of Clinical Oncology 32, no. 14 (2014): 1507–1515. Link: https://pubmed.ncbi.nlm.nih.gov/24515565/.

Morrow, M., K. J. Van Zee, L. J. Solin, et al. “Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma in Situ.” Journal of Clinical Oncology 34, no. 33 (2016): 4040–4046. Link: https://pubmed.ncbi.nlm.nih.gov/27510389/.

NSABP B-24 Review. “Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women with Ductal Carcinoma In Situ: NSABP B-24 Review.” Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC3341142/.

Sorin, V., et al. “Contrast-Enhanced Mammography: A Literature Review.” Journal of Clinical Medicine (2024). Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC11674923/.

Sundquist, L. M., et al. “Long-Term Results of the Swedish DCIS Trial (SweDCIS): Randomized Trial of Radiation Therapy After Sector Resection.” Link: https://pubmed.ncbi.nlm.nih.gov/19224841/.

U.S. Food and Drug Administration. FDA Updates Mammography Regulations to Require Reporting of Breast Density Information. March 2023 (effective September 10, 2024). Link: https://www.fda.gov/news-events/press-announcements/fda-updates-mammography-regulations-require-reporting-breast-density-information-and-enhance.

U.S. Preventive Services Task Force. Breast Cancer: Screening — Final Recommendation Statement. Rockville, MD: USPSTF, April 30, 2024. Link: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening.

Wright, H. K., et al. “Comparison of SCOUT Radar Reflector and Pintuition Magnetic Seed for Wireless Localization of Nonpalpable Breast Lesions.” 2025. Link: https://pubmed.ncbi.nlm.nih.gov/40946252/.